Led by an experienced team of medical research scientists, Oramed is a company focused on the commercial development of proprietary oral therapies. Currently, Oramed’s main focus is the treatment of diabetes via an oral insulin capsule, which has the potential to help millions of diabetics worldwide. Oramed’s oral insulin will better control diabetes by ingesting the capsule at an earlier stage of one’s treatment. Furthermore, based on Oramed’s patented technology, its top scientists are developing other methods of oral delivery for drugs and vaccinations which are currently not available in an oral form.
making managing diabetes as easy as
taking a pill

|
ORAMED is poised to develop a revolutionary new means of insulin delivery—an oral insulin , offering hope to nearly 200 million diabetics worldwide.
|
|
|
 |
|
Estimated diabetes costs in the United States in 2002
Total (direct and indirect): $132 billion
Direct medical costs:
$92 billion
Indirect costs (disability, work loss, premature mortality):
$40 billion 
As stated by the American Diabetes Association |
 |
|